The world of targeted therapies in kidney cancers: pitfalls, tips and tricks

References

• RiniBICampbellSCEscudierBRenal cell carcinomaLancet200937396691119113219269025
   PubMed Web of Science ®Google Scholar
• LjungbergBCampbellSCChoiHYThe epidemiology of renal cell carcinomaEur Urol201160461562121741761
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPOverall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinomaJ Clin Oncol200927223584359019487381
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMTARGET Study GroupSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med2007356212513417215530
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSRECORD – 1 Study GroupPhase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factorsCancer2010116184256426520549832
   PubMed Web of Science ®Google Scholar
• EscudierBPortaCSchmidingerMESMO Guidelines Working GroupRenal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201425Suppl 3iii49iii5625210086
   PubMed Web of Science ®Google Scholar
• Langrand-EscureJVallardARivoirardRSafety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life reportAnticancer Drugs201627542743227045782
   PubMedGoogle Scholar
• GoreMESzczylikCPortaCSafety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trialLancet Oncol200910875776319615940
   PubMed Web of Science ®Google Scholar
• HutsonTEBukowskiRMRiniBIEfficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinomaBr J Cancer201411051125113224434434
   PubMed Web of Science ®Google Scholar
• HaasNBManolaJUzzoRGAdjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialLancet2016387100322008201626969090
   PubMed Web of Science ®Google Scholar
• MotzerRJRiniBIBukowskiRMSunitinib in patients with metastatic renal cell carcinomaJAMA2006295212516252416757724
   PubMed Web of Science ®Google Scholar
• ArmstrongAJHalabiSEisenTEverolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trialLancet Oncol201617337838826794930
   PubMed Web of Science ®Google Scholar
• ProcopioGBellmuntJDutcherJSorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysisBr J Cancer2013108231131823322192
   PubMed Web of Science ®Google Scholar
• PatardJJBaumertHBensalahKLes membres du CCAFUCCAFU Recommendations 2013: Renal cancerProg Urol201323Suppl 2S177S204 French [with English abstract]24485292
   PubMedGoogle Scholar
• FerraraNHillanKJGerberHPNovotnyWDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNat Rev Drug Discov20043539140015136787
   PubMed Web of Science ®Google Scholar
• MolinaAMMotzerRJHengDYSystemic treatment options for untreated patients with metastatic clear cell renal cancerSemin Oncol201340443644323972707
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med2007356211512417215529
   PubMed Web of Science ®Google Scholar
• MaisonneuvePAgodoaLGellertRCancer in patients on dialysis for end-stage renal disease: an international collaborative studyLancet19993549173939910408483
   PubMed Web of Science ®Google Scholar
• CzarneckaAMKaweckiMLianFKornilukJSzczylikCFeasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experienceFuture Oncol201511162267228226260806
   PubMed Web of Science ®Google Scholar
• JosephsDHutsonTECoweyCLEfficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysisBJU Int201110881279128321244613
   PubMedGoogle Scholar
• ParkSLeeJParkSHTreatment of hemodialyzed patients with sunitinib in renal cell carcinomaChemotherapy201056648549121099221
   PubMedGoogle Scholar
• MasiniCSabbatiniRPortaCUse of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian surveyBJU Int2012110569269822364110
   PubMedGoogle Scholar
• VickersMMHengDYHemmelgarnBEiglBJTolerance of sunitinib in dialyzed patients with metastatic renal cell carcinomaClin Genitourin Cancer200973E104E10619815480
   PubMedGoogle Scholar
• IzzedineHEtienne-GrimaldiMCRenéeNVignotSMilanoGPharmacokinetics of sunitinib in hemodialysisAnn Oncol200920119019218801884
   PubMedGoogle Scholar
• YildizISenFKilicLCiftciRBasaranMIntolerance to sunitinib treatment in hemodialysis patients with metastatic renal cell carcinomaKorean J Urol2014551747624466402
   PubMedGoogle Scholar
• LiXSWuXZhaoPJEfficacy and safety of sunitinib in the treatment of metastatic renal cell carcinomaChin Med J (Engl)2011124182920292422040503
   PubMed Web of Science ®Google Scholar
• PatelPHSenicoPLCurielREMotzerRJPhase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinomaClin Genitourin Cancer200971242719213664
   PubMed Web of Science ®Google Scholar
• AbodundeOALevakaVeeraRRDesaiRNwekeNBerrouMColchicine toxicity precipitated by interaction with sunitinibJ Clin Pharm Ther201338324324523448320
   PubMed Web of Science ®Google Scholar
• AutierJEscudierBWechslerJSpatzARobertCProspective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitorArch Dermatol2008144788689218645140
   PubMed Web of Science ®Google Scholar
• LeeWJLeeJLChangSECutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinibBr J Dermatol200916151045105119558553
   PubMed Web of Science ®Google Scholar
• Gout attack: physiopathology, diagnosis, treatment, evolutionParisBichat University Hospital Pr Meyer [updated 2011]. Available from: http://www.rhumatologie-bichat.com/Cours%20D3%20Goutte.pdf. Article in French
   Google Scholar
• ZhangKWangXWangHEffect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549/DDP cisplatin-resistant lung cancer cell lineMol Med Rep20141042065207225109654
   PubMedGoogle Scholar
• BaiLYangJCOkJHMackPCKungHJEvansCPSimultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migrationInt J Cancer2012130112693270221792888
   PubMedGoogle Scholar
• KaramanMWHerrgardSTreiberDKA quantitative analysis of kinase inhibitor selectivityNat Biotechnol200826112713218183025
   PubMed Web of Science ®Google Scholar
• AntounSBaracosVEBirdsellLEscudierBSawyerMBLow body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinomaAnn Oncol20102181594159820089558
   PubMed Web of Science ®Google Scholar
• MirOCoriatRBlanchetBSarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinomaPLoS One201275e3756322666367
   PubMed Web of Science ®Google Scholar
• ChaïbiPMagnéNBretonSInfluence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patientsCrit Rev Oncol Hematol201179330230720888781
   PubMed Web of Science ®Google Scholar
• GuillotALevyAPacautCReappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinomaClin Genitourin Cancer201210314715222796529
   PubMedGoogle Scholar
• MazeronRAndersonBSupiotSParisFDeutschECurrent state of knowledge regarding the use of antiangiogenic agents with radiation therapyCancer Treat Rev201137647648621546163
   PubMed Web of Science ®Google Scholar
• de Castro JuniorGPuglisiFde AzambujaEEl SaghirNSAwadaAAngiogenesis and cancer: a cross-talk between basic science and clinical trials (the “do ut des” paradigm)Crit Rev Oncol Hematol2006591405016600618
   PubMed Web of Science ®Google Scholar
• MelicharBBracardaSMatveevVBEVLiN InvestigatorsA multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiNAnn Oncol20132492396240223803225
   PubMed Web of Science ®Google Scholar